Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Lac-Leamy

Oct 27, 2025 7:30 AM - Oct 28, 2025 3:40 PM

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

Canada Annual Meeting

The Canada Annual Meeting offers three tracks, Regulatory, Clinical, Safety and Pharmacovigilance!

Session 4, Track C: Patient Support Programs and Drug Safety: Compliance, Reporting, and Optimization

Session Chair(s)

Ricardo  Pasquel Cook, MD

Ricardo Pasquel Cook, MD

Safety Team Lead

Pfizer Inc., Canada

Anna  Bussel, MPharm

Anna Bussel, MPharm

Vice President Pharmacovigilance and Medical Information

ClaroPV Services Inc, Canada

As Patient Support Programs (PSPs) become increasingly integral to patient care - especially with the rise of injectable therapies - ensuring pharmacovigilance (PV) compliance and data quality is more critical than ever. This session explores the evolving PSP landscape in Canada and the U.S., highlighting key differences, challenges, and opportunities. Experts will share proactive strategies for designing compliant post-market surveillance workflows, optimizing AE reporting, and improving collaboration between PV and commercial teams. Attendees will gain practical insights into monitoring PSP-provider compliance, enhancing data quality, and aligning workflows with regulatory expectations to safeguard patient safety.

  • Patient Supports Programs and Drug Safety
    Riti Singh, Bayshore Healthcare (Bayshore Specialty Rx Ltd.)
  • Good Pharmacovigilance Practices Audits Of Patients Support Programs
    Agnes Jankowicz, Claropv Services Inc.
  • Patient Support Programs and Safety Reporting: An Industry Perspective
    Nadia Latif, Ipsen Biopharmaceuticals Canada Inc

Learning Objective :
  • Compare Canadian vs. U.S. regulatory expectations for Patient Support Programs (PSPs), using regional examples to highlight major differences
  • Outline effective strategies to design and monitor PSP workflows that improve adverse event (AE) reporting quality and ensure compliance
  • Apply KPIs to evaluate PSP effectiveness in pharmacovigilance and suggest enhancements for organizational processes

Speaker(s)

Riti  Singh, PharmD, MBA

Patient Supports Programs and Drug Safety

Riti Singh, PharmD, MBA

Bayshore Healthcare (Bayshore Specialty Rx Ltd.), Canada

National Director - Scientific Affairs, Quality, Ethics and Compliance

Nadia  Latif, MS

Speaker

Nadia Latif, MS

Ipsen Biopharmaceuticals Canada Inc., Canada

Senior Manager, Pharmacovigilance

Agnes  Jankowicz, MS

Good Pharmacovigilance Practices Audits Of Patients Support Programs

Agnes Jankowicz, MS

ClaroPV Services Inc, Canada

Vice President, Pharmacovigilance

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.